纵向血浆代谢组学指导食管鳞状细胞癌化疗免疫治疗的动态风险评估与饮食调节
Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
细胞因子诱导的杀伤细胞免疫治疗早期食管鳞状细胞癌的长期临床疗效
英文原题：Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma.
查看英文原题
Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
这些结果表明，CIK 细胞联合常规治疗可能延长患者的长期生存期，并可能作为早期 ESCC 治疗的一种联合治疗手段。
研究思路结论见上方概要
背景
在这项回顾性临床研究中，作者探讨了基于细胞因子诱导的杀伤（CIK）细胞的免疫疗法对食管鳞状细胞癌（ESCC）患者长期生存的影响。
方法
共纳入87例接受综合治疗的ESCC患者。其中，对照组43例，CIK治疗组44例。采用流式细胞术分析检测CIK细胞的表型及抗肿瘤功能。比较两组患者的临床特征，并采用Kaplan-Meier分析确定ESCC患者的生存估计。
结果
CIK细胞含有高比例的主要功能组分（CD3+CD56+组），并在体外对食管癌细胞表现出强大的杀伤能力。重要的是，在早期ESCC中，CIK组的总体生存期（OS）和无进展生存期（PFS）显著高于对照组。然而，与对照组相比，晚期ESCC患者在OS和PFS方面并未从基于CIK细胞的治疗中获益。
展开英文摘要原文
METHODS
A total of 87 patients with ESCC who received comprehensive treatment were enrolled in the study. Of these patients, 43 were in the control group and 44 were in the CIK treatment group. Flow cytometry analysis was performed to detect the phenotype and anti-tumor function of CIK cells. Clinical characteristics were compared between these two groups, and the survival estimates of ESCC patients were determined using Kaplan-Meier analysis.
RESULTS
CIK cells contained a high proportion of the main functional fraction (CD3 + CD56 + group) and exhibited a strong killing ability for esophageal cancer cells in vitro. Importantly, overall survival (OS) and progression-free survival (PFS) were significantly higher in the CIK group than in the control group in early-stage ESCC. However, patients with advanced-stage ESCC did not benefit from CIK cell-based therapy in terms of OS and PFS compared with the control group.
CONCLUSIONS
These results demonstrate that CIK cells combined with conventional treatments potentially prolong long-term survival of patients and may serve as a combined therapeutic approach for the treatment of early-stage ESCC.
论文信息
- 作者
- Liu Y、Zhang Z、Tian Y、Wang D、Liu S、Li L、Hao N、Qin G
- 第一作者单位
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, China.China
- 通讯作者单位
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, China; School of Life Sciences, Zhengzhou University, Zhengzhou, China; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou, China. Electronic address: yizhang@zzu.edu.cn.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Cytotherapy2022 May
- 原文标识
- PubMed 35219583 · DOI 10.1016/j.jcyt.2021.12.008